Blog

C. Ola Landgren Expands Myeloma Program at Sylvester Comprehensive Cancer Center

C. Ola Landgren/LinkedIn

Apr 22, 2025, 14:35

C. Ola Landgren Expands Myeloma Program at Sylvester Comprehensive Cancer Center

C. Ola Landgren, Leader, Translational and Clinical Oncology Program/Experimental Therapeutics at Sylvester Comprehensive Cancer Center, shared the following insightful post on LinkedIn:

“We keep on expanding our innovative and highly successful myeloma program in beautiful Miami!
We are looking to recruit a full-time (Advanced Practice Registered Nurse) APRN at the Division of Myeloma and Sylvester Myeloma Institute, University of Miami, Sylvester Comprehensive Cancer Center.

The perfect candidate for this new job is an APRN with focus on cutting-edge clinical care, modern treatment strategies, teamwork, with clinical experience from hematology, oncology, phase 1 clinic, and/or bone marrow transplantation care, and with interest in drug development and novel ideas.

Apply here.

We hope to hear from you soon!

Sylvester Comprehensive Cancer Center is the only NCI designated cancer center in South Florida. Our catchment area is over 6.2 million people. The Division of Myeloma and Myeloma Research Institute provides world-class care to a large number of myeloma patients in Miami, across the U.S., and internationally.

Our clinical trials portfolio is extensive; focusing on Phase 1 and Phase 2 clinical trials, we bring all the latest anti-myeloma drugs to our patients. Our world-class computational discovery research laboratory as well as our world-class epigenetic research wet laboratory are leading many innovative research studies, and we collaborate with other major centers worldwide.”

This post by C. Ola Landgren highlights the continued growth of the Sylvester Myeloma Institute in Miami. The program is seeking a full-time Advanced Practice Registered Nurse (APRN) with expertise in hematology, oncology, and clinical trial care. The initiative reflects the center’s focus on cutting-edge treatments, drug development, and international research collaboration in myeloma care.